Last reviewed · How we verify
NCT05275179
Pharmacokinetic of Posaconazole in Critically Ill Patients
trial testing Posaconazole Therapeutic Drug Monitoring in Therapeutic Drug Monitoring in 10 participants. Completed in 1 November 2022.
30 March 2022
Quick facts
| Lead sponsor | Universitätsklinikum Hamburg-Eppendorf |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 11 February 2021 |
| Primary completion | 30 March 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Posaconazole Therapeutic Drug Monitoring
Conditions studied
- Therapeutic Drug Monitoring — all drugs for Therapeutic Drug Monitoring →
- Critical Illness — all drugs for Critical Illness →
Sponsor
Universitätsklinikum Hamburg-Eppendorf — full company profile →
Who can join
18 and older, any sex, with Therapeutic Drug Monitoring or Critical Illness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The posaconazole pharmacokinetic in critically ill patients will be studied in a prospective, non-interventional, monocentric observational trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Posaconazole exposure in critically ill ICU patients: a need for action.
König C, Göpfert M, Kluge S, Wichmann D. · · 2023 · cited 7× · PMID 37498488 · DOI 10.1007/s15010-023-02078-9
Verify or expand the search:
- PubMed search for NCT05275179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Therapeutic Drug Monitoring
Currently open trials in the same condition.
- NCT06051253 — TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease · Phase 4 · recruiting
- NCT05283174 — The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Sh · recruiting
Other Universitätsklinikum Hamburg-Eppendorf trials
Trials by the same sponsor.
- NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
- NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
- NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
- NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
- NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05275179 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05275179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing